CDKN1B and neoplasm: The mixed clinical and rppa-based fingerprint fp160 has a special status since the three clinical parameters (Gleason primary score, tumor stage, psa) are routinely collected in the current clinical protocols, thus the marginal cost of setting up an assay for fp160 is associated with measuring the levels of CDKN1B and NF2.